ImmunoGen Past Earnings Performance
Past criteria checks 0/6
ImmunoGen has been growing earnings at an average annual rate of 2.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
2.8%
Earnings growth rate
21.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 6.2% |
| Return on equity | -113.0% |
| Net Margin | -210.3% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ImmunoGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 96 | -201 | 88 | 0 |
| 30 Jun 22 | 89 | -161 | 64 | 0 |
| 31 Mar 22 | 92 | -129 | 50 | 0 |
| 31 Dec 21 | 70 | -139 | 44 | 0 |
| 30 Sep 21 | 128 | -71 | 40 | 0 |
| 30 Jun 21 | 137 | -56 | 40 | 0 |
| 31 Mar 21 | 135 | -49 | 40 | 0 |
| 31 Dec 20 | 132 | -44 | 39 | 0 |
| 30 Sep 20 | 91 | -71 | 39 | 0 |
| 30 Jun 20 | 86 | -70 | 38 | 0 |
| 31 Mar 20 | 87 | -89 | 37 | 0 |
| 31 Dec 19 | 82 | -104 | 38 | 0 |
| 30 Sep 19 | 51 | -151 | 38 | 0 |
| 30 Jun 19 | 48 | -176 | 38 | 0 |
| 31 Mar 19 | 42 | -174 | 38 | 0 |
| 31 Dec 18 | 53 | -169 | 37 | 0 |
| 30 Sep 18 | 79 | -140 | 36 | 0 |
| 30 Jun 18 | 77 | -150 | 36 | 0 |
| 31 Mar 18 | 107 | -117 | 36 | 0 |
| 31 Dec 17 | 115 | -96 | 34 | 0 |
| 30 Sep 17 | 90 | -117 | 33 | 0 |
| 30 Jun 17 | 89 | -105 | 35 | 0 |
| 31 Mar 17 | 57 | -142 | 35 | 0 |
| 31 Dec 16 | 49 | -157 | 39 | 0 |
| 30 Sep 16 | 53 | -156 | 38 | 0 |
| 30 Jun 16 | 60 | -145 | 34 | 0 |
| 31 Mar 16 | 65 | -129 | 35 | 0 |
| 31 Dec 15 | 57 | -119 | 31 | 0 |
Quality Earnings: IMU is currently unprofitable.
Growing Profit Margin: IMU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMU is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: IMU has a negative Return on Equity (-112.97%), as it is currently unprofitable.